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This paper proposes a test for the existence of placebo eﬀects, as described by the so-called ex-
pectancy theory. This theory, which is the dominant medical theory of how placebo eﬀects operate,
posits that health outcomes rise in individuals’ beliefs about the probability that they are getting
ab e n e ﬁcial treatment and their beliefs about the eﬃcacy of that treatment. Blinded, randomized,
controlled trials provide near-perfect environments in which to test this theory because they oﬀer
objective, controlled manipulations of subjects’ beliefs about treatment. If the expectancy theory
is correct, outcomes in trials oﬀering a higher probability of receiving an experimental treatment
should be superior to outcomes in trials oﬀering a lower probability of receiving that treatment,
conditional on treatment assignment. The paper applies this test to data from over 200 trials of
anti-ulcer medications and ﬁnds robust evidence of placebo eﬀects in trials of H2-blockers (e.g., Zan-
tac, Tagamet and Pepcid) and of proton-pump inhibitors (e.g., Prilosec, Nexium, and Prevacid).
Indeed, trials of H2-blockers manifest placebo eﬀects that are 50 percent as large as the physiolog-
ical eﬀects of these medications. Because placebo eﬀects are not conﬁned to clinical trials, this
result suggests that the standard diﬀerence-in-means estimator of treatment eﬀects may seriously
underestimate the eﬃcacy of anti-ulcer medications.
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attributed to the physiological eﬀects of treatment or to the natural progression of disease. There
is a lively debate in the medical literature about whether placebo eﬀects actually exist. On
one side is, e.g., a recent New England Journal of Medicine article (Hrobjartsson and Gotzsche,
2001) that examines 114 studies with both a blinded placebo-control group and an unblinded no-
treatment group and ﬁnds few systematic diﬀerences in outcomes between these groups. This
result does not disprove the existence of placebo eﬀects because it is consistent with the theory
that members of unblinded no-treatment groups seek out alternative medication, which elevates
their health outcomes.
On the other side of the debate are, e.g., studies (Kirsch and Sapirstein, 1998; Kirsch and
Nicholls, 2002) that point to evidence that placebo-control groups in blinded trials often manifest
substantially improved health outcomes. These ﬁndings are weak support for placebo eﬀects
because the improvements could be due to the natural progression of disease. Better studies employ
a balanced-placebo design wherein subjects are ﬁrst randomized across treatments and then across
instructions about the value of treatment or whether one obtained placebo. Unfortunately, not
only are the results of these studies mixed (Marlatt and Rohsenow, 1980; Kirsch and Weixel, 1988;
Penick and Hinkle, 1964; Penick and Fisher, 1965), but their design is ethically questionable if not
illegal.
A common weakness of studies on both sides of the debate is that they do not begin with a clear
m o d e lo fp l a c e b oe ﬀects that can be deﬁnitively falsiﬁed. This paper addresses this shortcoming by
focusing on the dominant medical theory (Jensen and Karoly, 1991) for how placebo eﬀects operate.
This so-called expectancy theory posits that health outcomes rise in individuals’ beliefs about the
probability that they are getting a beneﬁcial treatment and their beliefs about the eﬃcacy of that
treatment (Pollo and Benedetti, 2001; Price and Nicholls, 1999). The paper formalizes this theory
by assuming that health outcomes are a function not just of the treatment, but also of the expected
value of treatment in the eyes of the patient.
The central insight of the paper is that randomized, controlled trials (RCT), if blinded, provide
an objective and controlled manipulation of beliefs that permits a relatively clean test of the
expectancy theory of placebo eﬀects. Informed consent reveals to subjects the ex ante probability
of obtaining treatment, but blinding ensures that they do not learn their ultimate assignment. This
1probability of treatment, along with subjects’ assessments of the relative eﬃcacy of the treatment,
aﬀects subjects’ beliefs about the expected value of the trial. If the expectancy theory is correct,
then this probability also aﬀects outcomes. More speciﬁcally, because enrollment in trials is
voluntary, trials only attract individuals who believe the treatment is better than the control. If
there exist placebo eﬀects, trials with a higher probability of treatment should produce better
outcomes, conditional on treatment assignment, than trials with a lower probability of treatment.
The paper applies this test for placebo eﬀects to data from over 200 RCTs of anti-ulcer med-
ications. The advantage of ulcer trials is that outcomes are objectively measured: ulcer healing is
veriﬁed by endoscopy. In trials where patients were asked for informed consent and thus had some
indication of their probability of treatment, a signiﬁcant, positive correlation is found between this
probability and outcomes in the treatment arms of trials of H2-blockers (e.g., Zantac and Tagamet)
and proton-pump inhibitors (e.g., Nexium and Prevacid). In trials without informed consent,
this correlation is diminished. Control arms also manifest evidence of signiﬁcant, though weaker
placebo eﬀects.
Section 1 presents a model of how individuals sort into trials. Section 2 formalizes the ex-
pectancy theory of placebo eﬀects. Section 3 derives testable predictions regarding trial outcomes
with and without placebo eﬀects. Section 4 tests these predictions against data from ulcer trials.
The appendix oﬀers proofs for the propositions in the text.
1 TREATMENT STRATEGIES
This section presents a model of how individuals who are currently ill sort among treatment strate-
gies. Suppose there are two possible, future health states: continued illness ¯ y and recovery y,w h e r e
¯ y>y . (The analysis can easily be extended to the case of continuous health variables.) Treatments
are lotteries over these two states. For now, assume that there exist only two treatments: no treat-
ment (k =0 ) and an experimental treatment (k =1 ). Let yki be the random variable that describes
individual i’s health outcome given treatment k.D e ﬁne pki =P r{yki =¯ y|no placebo eﬀects}.I n
the case of no treatment, this probability is simply a function of the natural progression of disease.
For the experimental treatment, this probability is also a function of the physiological eﬀects of
treatment. Although a slight abuse of medical terminology, the sum of natural progression and
2the physiological eﬀects of treatment will be called the speciﬁce ﬀect of treatment.
Treatments are to be distinguished from treatment strategies. The latter are deﬁned to be
lotteries over treatments, and thus compound lotteries over health states. Initially assume that
there are only two feasible treatment strategies: certain consumption of no treatment (s =0 )o r
enrollment in a randomized, placebo-controlled trial (RPCT) that is blinded (s = BT). The latter
strategy entails a probability d of receiving the experimental treatment and probability 1 − d of
receiving a placebo. This narrow set of feasible strategies is appropriate under two conditions.
First, the experimental treatment is not available outside the context of the trial because, e.g.,
the government has not approved it. Second, individuals are only oﬀered one lottery and in this
lottery subjects do not learn which treatment they actually consume. This condition is reasonable
because trials are costly to conduct and investigators prefer blinded trials due to concerns about
attrition.
A common feature of trials important to the analysis in this paper is that enrollment is voluntary
and subject to informed consent. As part of this disclosure, it is typically required that subject be
given information about the probability that they will receive the experimental treatment. See,
e.g., 21 C.F.R. §§ 7.3(f), 20.25 (United States). Individual i’s belief about the probability that
she is consuming treatment k is δki. For simplicity, assume that subjects do not consume more
than one treatment, so
P1
k=0 δki =1 . From the individual’s perspective, strategies are deﬁned by
the vector of beliefs δi =( δ0i,δ1i). A strategy of certain consumption of no treatment is deﬁned
by δi =( 1 ,0). The trial strategy reveals the probability of treatment but not ultimate treatment
assignment, so δi =( 1−d,d). In order to abstract from problems with attrition, assume that there
is no unblinding due to, e.g., subject sampling (Philipson and DeSimone, 1997) on outcomes. The
subject’s belief about the speciﬁce ﬀect of treatment k is πki. (No position need be taken on how
beliefs about speciﬁce ﬀects are formed. Diﬀerent tests will be proposed for diﬀerent assumptions
about the relationship between eﬃcacy and beliefs.)
Individuals are assumed to have preferences that conform to Savage’s axioms (Savage, 1954) and
thus permit representation in the form of a subjective expected utility function. Individuals draw
utility from health and non-health consumption. For simplicity, assume further that individuals
have identical and additively separable utility functions. Let u(y) be the utility from health
outcome y,w i t hu0 > 0, u00 < 0. The expected utility of strategy s to individual i is a weighted
3s u mo ft h eu t i l i t yf r o me a c hh e a l t ho u t c o m e ,w i t ht he weights being her subjective beliefs about the
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that an individual knows her treatment status outside the context of a trial, her subjective belief
is π0
i = π0i. Belief about the probability of recovery given a blinded trial strategy depends on the
probability of being given the experimental treatment: πBT
i = dπ1i+(1−d)π0i. Each individual is
assumed to sort into that strategy which maximizes her utility. (Sorting based on expected utility
is not a necessary condition for the tests of placebo eﬀects set forth in the next section. All that
is required is a rational actor model that permits sorting based on beliefs about the speciﬁce ﬀects
of strategies. An advantage of expected utility theory is that it permits this model of sorting into
treatment strategies conveniently to be generalized to take into account, e.g., diﬀerence in costs
across strategies or attrition based on self-sampling if necessary.)
In order to determine the sorting of individuals to strategies, one must know the distribution
of beliefs about treatment among the population. Since the object of these beliefs is the actual
eﬃcacy of treatment, let gp give the probability distribution function of pi =( p0i,p 1i) across
the population. Let gπ give the probability distribution for πi =( π0i,π1i). All distributions
discussed are assumed to be well-deﬁned. The expectations operator Eg (·) will be employed when
expectations are taken over the joint distribution of (pi,πi).
2 EXPECTANCY THEORY OF PLACEBO EFFECTS
According to the expectancy theory of placebo eﬀects, patients manifest changed health outcomes in
response to expectations regarding treatment. In particular, the more eﬀective a patient expects
a treatment to be, the better her response to it. The more likely a patient thinks she is to
get a beneﬁcial treatment the better is her health outcome holding constant whether or not she
receives treatment. This section formalizes this theory with a simple model of health outcomes as
a weighted average of the speciﬁce ﬀects of one’s treatment and beliefs about the speciﬁce ﬀects of
one’s treatment strategy:
Pr{yki =¯ y|ak,p ki,πs
i} =( 1− ak)pki + akπs
i, (1)
4where ak ∈ [0,1] for all k. The relevant beliefs are not those about treatment k but about strategy
s because, if an individual enters a blinded trial, she does not learn whether she has consumed
treatment k. The parameter ak indicates the relative importance of beliefs in determining the
health outcome given consumption of treatment k.P l a c e b o e ﬀects are deﬁned to exist for treatment
k if ak > 0.T h e i n ﬂuence of beliefs is assumed not to vary across individuals. The purpose of this
assumption is to facilitate application of the test for the existence of placebo eﬀects in section 3 to
ulcer trial data, which are aggregated to the level of treatment groups so estimation of a random
eﬀects model is not feasible. An implication of this assumption is that the inﬂuence of placebo
eﬀects is independent of individuals’ beliefs about the eﬃcacy of diﬀerent treatments. There is no
compelling medical reason to think otherwise.
3 TESTS FOR EXISTENCE OF PLACEBO EFFECTS
This section employs the models of sections 1 and 2 to generate predictions regarding outcomes
observed in clinical trials with and without placebo eﬀects. Any diﬀerence in predictions can be
used to test for the existence of placebo eﬀects. The results are summarized in table 1.
Initially, assume that only individuals who believe that the experimental treatment is superior
to no treatment (π1i >π 0i) sort into the trial. (The next section will justify this assumption.)
Deﬁne ˜ πki = πki −π0i, the relative beneﬁto ft r e a t m e n tk over no treatment, so that π1i >π 0i can
be written ˜ π1i > 0. In the absence of placebo eﬀects, the mean outcome observed in the group
that receives treatment k in a blinded RPCT is Eg [yk|˜ π1 > 0] = Eg [pk|˜ π1 > 0]. (Henceforth, i
subscripts are dropped to simplify notation whenever their use does not add to the exposition.) In
the presence of placebo eﬀects, the mean outcome is
Eg [yk|˜ π1 > 0,d]=( 1− ak)Eg [pk|˜ π1 > 0] + ak{dEg [π1|˜ π1 > 0] + (1 − d)Eg [π0|˜ π1 > 0]}.
Without placebo eﬀects, outcomes are solely a function of the speciﬁce ﬀects of treatment. The
probability of treatment or, equivalently, the share treated is irrelevant. With placebo eﬀects,
outcomes are also a function of beliefs about speciﬁce ﬀects of the treatment strategy. Because
these beliefs depends on the probability of receiving the experimental treatment, i.e., πBT
i = dπ1i+
5(1 − d)π0i, so too will outcomes. More speciﬁcally, an increase in the share treated lifts mean
outcomes in each group of the trial: ∂Eg [yk|˜ π1 > 0,d]/∂d = aEg [˜ π1|˜ π1 > 0] > 0.A s t h e s h a r e
treated rises, individuals’ expectations of the trial rise because there is a better chance of getting
the experimental treatment, which is thought to be better than no treatment. These expectations
translate into better average outcomes when there exist placebo eﬀects. This yields the following
test for placebo eﬀects:
Proposition 1 Suppose individuals enroll in a blinded RPCT if and only if ˜ π1i > 0. If trials that
have higher treatment shares but are otherwise identical yield higher mean outcomes conditional on
treatment, then there exist placebo eﬀects.
This is the central theoretical result of the paper. It is robust to the functional form of health
outcomes.
3.1 Self-Selection
This section justiﬁes the assumption in proposition 1 that individuals enroll in a blinded RPCT
if and only if they believe that the speciﬁce ﬀects of the experimental treatment are superior to
those of no treatment. This sorting is a direct implication of individual self-selection into the
type of trial described in section 1. In that context, expected utility maximization implies that
individual i will enroll in a trial if and only if the probability of recovery given enrollment in a
blinded RCT is greater than the probability of recovery given no treatment. If subjects do not
take placebo eﬀects into account when deciding whether to enroll, this condition can be written
πBT
i = dπ1i +( 1− d)π0i >π 0i and is satisﬁe di fa n do n l yi f˜ π1i > 0. This condition does not
depend on the share treated. This result yields the following conclusion.
Proposition 2 Given the model of treatment strategies and preferences in section 1, self-selection
implies that individuals will enroll in a blinded RPCT if and only if ˜ π1i > 0. Therefore, the test
for placebo eﬀects in proposition 1 is valid for this model.
The test remains valid even if subjects take placebo eﬀects into account when deciding whether
to enroll in trials. (An expected utility representation for preferences is feasible in this case if beliefs
about the speciﬁce ﬀects of treatments are treated as state variables.) The individual assesses the
6value of the blinded trial to be πBT
i = d[(1 − α1i)π1i + α1iπBT
i ]+( 1− d)[(1− α0i)π0i + α0iπBT
i ],
where αki is the individual’s belief regarding the inﬂuence ak of beliefs on outcomes. Implicit in this
formulation is the assumption that beliefs about the inﬂuence of beliefs are independent of beliefs
about the speciﬁce ﬀects of treatments. A little algebra reveals that the condition πBT
i >π 0i again
collapses to ˜ π1i > 0. Proposition 2 is not valid, however, if investigators oﬀer individuals incentives
such as cash or in-kind beneﬁts to participate in a trial. Such payments may induce individuals
who believe that no treatment is superior to experimental treatment to enroll. An increase in the
share treated lowers the expectations and thus outcomes of these individuals. The overall eﬀect of
an increase in the share treated will be ambiguous.
3.2 Conventional Treatment
Thus far it has been assumed that there are only two treatments and two strategies. If individuals
have available a third treatment and strategy, namely conventional treatment outside the context
of a trial, there is the possibility of self-selection based on the share treated. If there is also
a correlation between individual beliefs – which drive sorting – and outcomes, then it is not
obvious that the test for placebo eﬀects set forth in proposition 1 will work. Without placebo
eﬀects, the share treated may aﬀect outcomes through self-selection. With placebo eﬀects, share
treated will aﬀect outcomes both due to a direct relationship between beliefs and outcomes and due
to self-selection. In the presence of a conventional alternative, self-selection is in eﬀect noise that
may obscure identiﬁcation of any direct relationship between beliefs and outcomes. One solution
is to rely on the fact that placebo eﬀects imply a positive relationship between share treated
and outcomes and search for conditions under which self-selection implies a negative relationship
between share treated and outcomes. Under these conditions, one could continue to test for placebo
eﬀects by searching for a positive relationship between share treated and outcomes. This section
sets forth these conditions, which, it turns out, are fairly reasonable.
To see that the presence of a conventional treatment implies self-selection based on share treated,
let k =2indicate the conventional treatment. An individual will now enroll in a blinded RPCT if
a n do n l yi fdπ1i +( 1− d)π0i > max{π0i,π2i} or, equivalently,
˜ π1i > max{0, ˜ π2i/d}. (2)
7In words, an individual will enroll in a trial so long as the expected value of its lottery over the the
experimental treatment and no treatment is greater than the value of no treatment or conventional
treatment for sure. Based on the subject’s beliefs, if no treatment is superior to the conventional
alternative, she will enroll if an only if the experimental treatment is better than no treatment
– the same selection condition as in the case without a conventional treatment. If, however, the
conventional treatment is better than no treatment, but worse than the experimental treatment, the
enrollment decision will depend on the share treated. If along the continuum from the experimental
treatment to no treatment, the conventional treatment is closer to the experimental treatment, it
will take a high probability of obtaining the experimental treatment to attract an individual to
the trial. If the conventional treatment is closer in eﬃcacy to no treatment, then even a small
probability of obtaining the experimental treatment may attract the individual to the trial.
Examining solely the subpopulation for which the share treated aﬀects the enrollment decision,
the following proposition gives conditions under which an increase in the share treated reduces
average beliefs about the speciﬁce ﬀects of the experimental treatment among the members of the
subpopulation that enroll.
Proposition 3 Suppose that Eg [˜ πki|π0i]=Eg [˜ πki];t h a t˜ πki > 0 for k =1 ,2; and that (ln ˜ π1i,ln ˜ π2i)
have a non-degenerate log-concave or log-convex joint density with mean (µ1,µ 2) and variance Σ.
Deﬁne uki =l n˜ πki−µi, Wi = u1i−u2i, σ = σ11+σ22−2σ12, b1 =( σ11 − σ12)/σ, b2 = a1−1,a n d
Vi = b1u2i − b2u1i. By construction ui = biWi + Vi,w h e r eWi and Vi are uncorrelated. Suppose
further that Wi and Vi are actually independent. Deﬁne ρ12 = corr(ln ˜ π1i,ln ˜ π2i).I f σ11 >σ 12 or,
equivalently, ρ12 <σ 1/σ2,t h e n∂Eg [π1i|˜ π1i > ˜ π2i/d]/∂d ≤ 0 and ∂Eg [π0i|˜ π1i > ˜ π2i/d]/∂d =0 .
Note three things. First, one can write πki = π0i +˜ πki,f o rk =1 ,2. Because natural
progression is deﬁned as the probability of recovery without treatment, this equation says that ˜ πki
is individual i’s beliefs about the physiological eﬀects of treatment k. Therefore, the assumption
that ˜ πki and π0i are independent implies that the physiological eﬀects of k are independent of the
natural progression of disease. This assumption ensures that selection pressures due to changes
in treatment share do not aﬀect the distribution of beliefs about no treatment among enrollees.
Second, the assumption that (ln ˜ π1i,ln ˜ π2i) is log-concave or convex is not very restrictive. The class
of log-concave densities is itself quite large. It includes, e.g., the bivariate normal distribution.
8In that case, the fact that Wi and Vi are (by construction) uncorrelated implies they are also
independent. Finally, proposition 3 is robust to the use of exclusion and inclusion criteria when
selecting enrollees so long as these criteria are independent of beliefs about treatment eﬃcacy. The
prediction is also robust to imperfect informed consent so long as whether candidates are informed
of d via informed consent is independent of the value of d.
Proposition 3 says that, so long as the covariance between (log) beliefs about the physiological
eﬀects of the experimental and conventional treatments is less than the variance of (log) beliefs about
the experimental treatment, changes in the share treated, if anything, reduce enrollees’ expectations
regarding the experimental treatment. From the deﬁnition of the correlation coeﬃcient, it is
obvious that the condition on the covariance is satisﬁed whenever the variance of beliefs about
the physiological eﬀects of the experimental treatment is greater than the variance of beliefs about
the conventional treatment. In this light, the condition on the covariance does not appear at all
unreasonable. The experimental treatment, by virtue of being new, will be associated with greater
uncertainty in beliefs among the patient population than the conventional treatment.
The intuition behind proposition 3 begins with the observation that the trial only attracts indi-
viduals who believe that the experimental treatment is so much better than conventional treatment
that, even with the risk of obtaining no treatment at all, enrolling in the trial is a superior strat-
egy to conventional treatment. If one alters a trial to increase the probability of obtaining the
experimental treatment, a patient who is marginally not optimistic (or marginally too pessimistic
about no treatment) enough about the experimental treatment to have risked randomization into
the placebo-control group before may now be willing to take that risk because it is smaller.
This logic is valid only if individuals who are optimistic about the experimental treatment aren’t
too optimistic about conventional treatment as well. If individuals who are more optimistic about
the experimental treatment are also (suﬃciently) more optimistic about conventional treatment,
individuals who are more optimistic about the experimental treatment are not more likely to join a
trial at any given level of share treated. Although the value of trial is higher given these individuals’
optimism about the experimental treatment, so is their optimism about the conventional alternative.
If these individuals are suﬃciently optimistic about the alternative, they may prefer it to enrollment
in the trial despite their high expectations for the experimental treatment.
Self-selection implies that trials with diﬀerent treatment shares may have enrollee populations
9with diﬀerent beliefs about each treatment. If there is no correlation between individual beliefs
and individual outcomes, share treated will not aﬀect outcomes in the absence of placebo eﬀects.
Although share treated may aﬀect outcomes in the presence of placebo eﬀects, the direction of the
relationship is not obvious. Nevertheless, one can test for placebo eﬀect by checking for any sort
of correlation between treatment shares and outcomes.
If, however, individual beliefs and individual outcomes are correlated, treatment shares will
aﬀect outcomes even in the absence of placebo eﬀects. It is reasonable to suppose this correlation
is positive. If it were negative, that would imply individuals who respond to well to treatment
estimate that they do not, and those that do not respond well estimate that they do. Although
one might suppose individuals over- or under-estimate treatment response, surely individuals do
not guess their personal response in the manner suggested by a negative correlation. Therefore, it
is assumed that treatment eﬃcacy and beliefs about eﬃcacy are related according to the function
pki = f (πki)+vki, (3)
where f is everywhere continuously diﬀerentiable, f0 > 0,a n dvki is independent of πk0i0 for all (k0,i 0)
and of vk0i0 for all (k0,i 0) except (k0 = k,i0 = i). The error term vki reﬂects error in predictions of
speciﬁce ﬃcacy by individual i. This assumption permits the following proposition.
Proposition 4 Suppose ∂Eg [π1i|˜ π1i > ˜ π2i/d]/∂d ≤ 0 but ∂Eg [π0i|˜ π1i > ˜ π2i/d]/∂d =0 .I f t r i a l s
that have higher treatment shares but otherwise are identical yield higher mean outcomes in the
experimental treatment groups or yield diﬀerent mean outcomes in no treatment groups, then there
exist placebo eﬀects.
The change in trial outcomes due to a change in share treated is a weighted sum of the change
in the speciﬁce ﬀects of the assigned treatment given self-selection, the change in beliefs about the
speciﬁce ﬀects of the trial strategy given self-selection, and the change in beliefs about the speciﬁc
eﬀects of the trial strategy holding self-selection constant:
∂Eg [yk|s = BT]
∂d
=( 1− ak)








+ ak˜ π1 (4)
The last term is simply the physiological eﬀects of the experimental treatment, which sorting
10implies is positive regardless of the share treated. The second term in (4) is non-zero only in the
presence of a conventional-treatment option. Proposition 3 gives the conditions under which an
increase in the share treated lowers average beliefs about the speciﬁce ﬀects of the experimental
treatment and leaves unaltered average beliefs about the speciﬁce ﬀects of no treatment. This
implies that the change in beliefs about the speciﬁce ﬀects of the trial strategy is negative in both
the experimental-treatment and the no-treatment groups. The ﬁrst term in (4) is non-zero only if
the speciﬁce ﬀects of the assigned treatment and beliefs about those speciﬁce ﬀects are correlated
– where the direction of causation runs from speciﬁce ﬀects to beliefs because subjects form beliefs
to predict speciﬁce ﬀects. If the correlation is positive, proposition 3 implies that the ﬁrst term is
negative in the experimental treatment group and zero in the no treatment group.
If there are no placebo eﬀects, there is no weight (ak =0 ) assigned to the second and third terms
in (4), so changes in speciﬁce ﬀects are all that drive outcomes. An increase in the share treated
ought to lower outcomes in the experimental-treatment group given self-selection. There should be
no change in the no-treatment group. If there are placebo eﬀects (ak > 0), then the last two terms
in (4) have positive weight. This adds a negative and positive term to the change in outcomes
in both groups. According to proposition 4, since outcomes in the experimental-treatment group
fall with the share treated even without placebo eﬀects, the presence of placebo eﬀects can only be
conﬁrmed if outcomes in this group rise with the share treated. (Of course this implies that the
test for the experimental group is prone to false negatives. It is possible that placebo eﬀects exist
but that self-selection, which tends to lower outcomes, overwhelms it.) In contrast, since outcomes
in the no-treatment group should be unaﬀected by changes in the share treated without placebo
eﬀects, the presence of placebo eﬀects can be conﬁrmed if outcomes in this group respond at all to
a change in the share treated.
The results from this section apply to conventional control trials. All that is required is that
one switch the subscripts k =0and k =2 . The results can also be extended to the case where
individuals take placebo eﬀects into account when choosing treatment strategies. The selection
equation will be ˜ π1i > max{0,h(d)˜ π2i},w h e r eh(d)=[ d˜ α1i +( 1− d)˜ α0i]/d˜ α1i and ˜ αki =1−αki.
Again, the population of enrollees will depend on the share treated. If the speciﬁce ﬀects of a
treatment and beliefs about those speciﬁce ﬀects are uncorrelated, any change in outcomes with the
share treated is evidence of placebo eﬀects. If speciﬁce ﬀects and beliefs are positively correlated,
11then any test for placebo eﬀects will depend on the nature of self-selection. Because h0 (d) < 0 for
d>0.5, propositions 3 and 4 are valid for trials where more than half of enrollees are treated.
4 APPLICATION TO ULCER TRIALS
Of the handful of studies that claim to ﬁnd evidence to support the expectancy theory of placebo
eﬀects, Skovlund (1991) and Pollo and Benedetti (2001) are likely the best. The former found that,
conditional on assignment to the treatment or control group, subjects in a placebo-controlled trial
of the painkiller paracetamol manifested better outcomes than those in a conventional controlled
trial of the same drug. The latter gave post-operative subjects a saline drip; randomized subjects
across three instructions about the drip: no comment, the drip is a potent painkiller or placebo,
and the drip is a potent painkiller; and separately oﬀered subjects the painkiller buprenorphine
on demand. The ﬁrst instruction induced the greatest demand for buprenorphine and the third
the least. While these studies are insightful, they are not compelling support for the expectancy
theory. They have small sample sizes and examine subjectively-measured outcomes, namely patient
self-reports of pain levels.
This paper addresses these shortcoming by examining nearly 200 trials of anti-ulcer medica-
tions, which permit an objective measure of outcomes. Ulcers are the erosion of the mucous lining
in the stomach or small intestine and are judged healed only via endoscopy by the investigator.
Three types of medication are considered. The ﬁrst type, H2-blockers, was introduced in 1977.
The most popular brands are Tagamet (cimetidine), Zantac (ranitidine), and Pepcid (famotidine).
H2-blockers prevent the production of acid in the stomach. The second type of medication,
prostaglandins, was introduced in 1987. The most common prostaglandins are misoprostil and
enprostil. These drugs build up and thus repair the mucous lining of the stomach and intestine.
The third class, proton-pump inhibitors (PPIs), and were introduced after prostaglandins. The
most popular brands are Prilosec (omeprazole), Nexium (esomeprazole) andP r e v a c i d( l a n s o p r a -
zole). Like H2-blockers, these medications prevent the production of acid in the stomach. A
distinguishing feature of these medications is that they oﬀer a much higher chance of healing an
ulcer than do antacids, which are alkali that absorb acid in the stomach.
That being said, it is now recognized that 90% of non-gastric ulcers are caused by the bacteria
12heliobacter pylori. These infections are usually treated with a combination of antibiotics and H2-
blockers or PPIs. This paper tests for placebo eﬀects in trials where H2-blockers, prostaglandins or
PPIs are used in isolation. These trials typically precede the change to antibiotic-based treatments.
4.1 Data
The data set (available from the author) includes the published results from over 200 clinical trials
studying treatment for pre-pyloric, pyloric and duodenal ulcers. Each of the trials is randomized,
parallel-armed, and double-blind, and employs either a placebo, antacid, bismuth subcitrate or
conventional control. If conventional controls are employed, they are from either the same or a
previous class of medication as the experimental treatment. Importantly, subjects in 197 of the
trials were asked for informed consent prior to enrollment. Hence it is reasonable to suppose
that subjects in those trials had some indication of their chance of obtaining the experimental
treatment.
Data were gathered on the characteristics of trials and of subjects. Data on subjects are
aggregated to the arm- or group-level. For example, there are data on the average age of subjects
assigned to any given treatment group, but not the age of each subject assigned to that group.
Although there are data on subjects in a group as of the date that they are randomized into the
group, precise information on how the group changes due to attrition are not available. This
omission is handled in three ways, by assuming those who attrite out heal at the same rate as those
who remain (method 1), all heal (method 2), or all do not heal (method 3). Table 2 provides
summary statistics for the data. Each observation represents a measurement on the indicated
arm of the indicated type of trial. Means and standard deviations are calculated weighting each
arm in proportion to the number of subjects evaluated per protocol, regardless of the number of
measurements on the arm. Frequency of medication and total dosage are not provided for control
arms because such variables are meaningless for placebo arms.
There are several things to note about the data. First, there are more groups given the
experimental treatment than given the control. The reason is that each trial typically involves one
control arm but multiple experimental treatment arms. Typically these arms will vary the total
daily dosage or the daily frequency of medication. While individuals may have diﬀerent beliefs
about eﬃcacy of each treatment v. no treatment, it is assumed that individuals do not have reﬁned
13beliefs about eﬃcacy by dosage. Second, the probability of active treatment is estimated by one
minus the probability of randomization into the placebo, antacid or bismuth subcitrate group, or
a lower-class ulcer medication. PPIs are the highest class and H2-blockers the lowest class drug.
Trials with same-class controls are assumed to have a probability of treatment equal to one. Third,
the antacid-permitted variable is coded from 1 to 5. One indicates that subjects were prohibited
from taking antacids, two that subjects were discouraged from taking antacids, three that subjects
were permitted to take antacids (or the study did not counsel subjects on antacids), four that
antacids were provided, and ﬁve that antacids were required.
4.2 Empirical Model
Assume that the speciﬁce ﬀects of treatment k on individual i enrolled in trial j are a deterministic,
linear function of the vector xij, which includes a constant, clinical and demographic variables on
individual i, and structural features of trial j: pkij = β0
kxij. This is a strong assumption, but
because the ulcer trial data are rather coarse there is little beneﬁt from a more nimble parame-
terization of pkij. Assume that beliefs regarding speciﬁce ﬀects are given by πkij = γ0
kxij + εkij,
where εkij is independent of xij and is i.i.d. mean-zero across individuals, trials, and treatment
states, with mean zero and variance σε. The condition on εkij implies that individual errors in
predicting speciﬁc treatment response do not depend on the treatment. If γk = βk, then this
parameterization of beliefs implies rational expectations.
Because trials often take multiple measurements on each individual, a treatment’s eﬀect is cast
as a hazard rate. Assuming it is constant over time, (1) and the assumed parameterization of
(pkij,πij) imply −lnSijk (t)/t = θ(x)kxij + θ(xd)kdjxij + ηijk,w h e r eSijk (t) gives the probability
of still having an unhealed ulcer on date t, the right-hand side is the hazard rate into healing,
θ(x)k =( 1− ak)βk + akγ0, θ(xd)k = ak (γ1 − γ0),a n dηijk = akdjε1ij + ak(1 − dj)ε0ij. Summing
over individuals and dividing by njk, the number of subjects enrolled in treatment arm k of trial j,
yields the regression equation −hlnSjk(t)i/t = θ(x)k¯ xjk + θ(xd)kdj¯ xjk +¯ ηjk.T h e l e f t - h a n d s i d e i s
approximated, ﬁrst, by a ﬁrst-order Taylor approximation around ¯ Sjk(t), the average probability
of remaining ill at t, which in turn the observed group survival rate. Approximating ¯ Sjk(t) is
diﬃcult because data on subjects who attrite out of the trials are not available. Therefore, ¯ Sjk(t)
is approximated with ¯ yjkt under three diﬀerent assumptions about the healing rate of those who
14attrite (methods 1 - 3 referenced earlier).
The regression equation that is ultimately estimated is
−ln(¯ yjkt)/t = θ(x)k¯ xjk + θ(xd)kdj¯ xjk + ωjk,( 5 )
where the unit of time is one day and ωjk =¯ ηjk + ujkt + vjkt. The error term ujkt is from
approximating ¯ Sjk(t) with ¯ yjkt. The Lagrange remainder from approximating hlnSjk(t)i with
ln ¯ Sjk(t) is absorbed into the coeﬃcient on the constant. For simplicity this is left out of the
deﬁnition of θ(x)k. The error term vjkt captures the variation in the remainder across arms and
trials.
Because the relevant hazard rate, Pr{yki =¯ y|s},i sc o n ﬁned by assumption to [0,1],t h ee m -
pirical model requires estimation of a linear probability model. While that model has ﬂaws, it is
not wholly inappropriate for the application in this paper. As a theoretical matter, the dependent
variable in (5) can range from (0,∞). Moreover, because individuals in an arm are aggregated,
the error term is more likely to resemble a normal distribution.
In the presence of a conventional alternative, the tests for placebo eﬀects set forth in section 3
may be complicated by self-selection based on share treated, which implies that E (εkijdj|s = BT) 6=
0. This problem is addressed by including trial- and subject-level covariates that may capture selec-
tion. An alternative approach is to isolate a subsample of trials for which there is no conventional
alternative to the experimental treatment. This is only possible with H2-blocker trials before 1987,
when prostaglandins were introduced. For each of the other classes of drugs, H2-blockers are a
conventional alternative. A third approach to selection is to assume E (εkijdj|s = BT)=0but
partition ¯ xj =( ¯ xo
j, ¯ xu
j),w h e r e¯ xo
j is observable but ¯ xu
j may not be. Suppose that ¯ xo
j is chosen such
that, as a theoretical matter, it ought to be θo
(xd)kdj¯ x1
j > 0 and that, given that selection pressures
depend on dj, θu
(xd)kdj¯ xu
j = φ(xd)kd2
j + ejk,w h e r eejk is independent of dj and ¯ xo
j. If selection is
a problem but there are no placebo eﬀects, θu
(xd)k and thus φ(xd)k should be zero. If the estimate
of φ(xd)k is signiﬁcantly diﬀerent from zero, then there must exist placebo eﬀects or selection is not
a problem. These alternative approaches yield, if anything, stronger evidence of placebo eﬀects
than when selection is controlled with appropriate covariates.
It should be noted that (5) was modiﬁed and estimated as a generalized linear model with a
15log link and survival distributed binomial or gamma. The results are similar, but nearly every
covariate speciﬁcation performs worse on Pregibon’s (Pregibon, 1980) link test when survival is
assumed gamma. In addition, a proportional hazard model was also estimated and produced
somewhat stronger evidence of placebo eﬀects. The coeﬃc i e n to nt i m ei sp o s i t i v ea n ds i g n i ﬁcant,
suggesting the risk of healing rises over time. However, few covariate speciﬁcations pass the link
test.
4.3 Results
Table 3 presents results for H2-blocker trials. Estimation was by feasible GLS. Observations were
weighted such that each arm makes a contribution to estimates in proportion to the number of
subjects in the arm, regardless of the number of measurements made on each arm. The regression
model suggests that the variance of error terms depends on the share randomized into each arm.
However, only one randomization share per trial – namely the share not given a non-healing or
lower class control – is measured. Therefore group-wise heteroskedasticity is permitted at the
trial-level, but not at the arm-level. No further structure is imposed on the variance-covariance
matrix. Only estimates where the dependent variable is calculated assuming subjects who attrite
out heal at the same rate as those who are evaluated are reported. Results from regressions which
assume that those who attrite out either all heal or all do not heal are not materially diﬀerent.
Four speciﬁcations of ¯ xj are estimated: (1) includes a constant and dj; (2) adds trial-level
variables (antacid usage, daily frequency of medication, total daily dosage of medication, total
daily dosage of the more common drugs in the relevant class of medications) and their interactions
with dj; (3) adds subject-level variables (sex, smoker, and age) and their interactions with dj;a n d
(4) removes the trial-level variables and their interactions with dj from (3). Each speciﬁcation is
checked against Pregibon’s link test. Those that fail are marked with a dagger (†). The residuals
were checked for but did not reveal troubling patterns.
The ﬁrst four columns of table 3 present results for treatment arms and diﬀerent speciﬁcations
of ¯ xj; the last four do the same for control arms. The ﬁrst panel of the table gives the number
of studies, arms, measurements on arms, and subjects included in each regression sample. The
basic unit of observation is a measurement on an arm. (Although a number of observations are
dropped because the survival rate is zero, the results are unchanged if survival rates of, e.g., 0.01, are
16substituted for survival rates of zero.) Although coeﬃcient estimates are omitted, the second panel
provides F-tests of the joint signiﬁcance of certain subsets of regressors interacted with dj.T h e i r
purpose is to test whether placebo eﬀects operate through any of these subsets of variables. The
main parameter of interest in this paper is the marginal eﬀect of share treated on the daily hazard
rate into the health state. Because the estimate for this marginal – ∂[−ln(¯ yjkt)/t]/∂dj = ˆ θ(xd)k¯ xj
– depends on the value of covariates, the third panel gives the estimated marginal eﬀect (and
standard deviation) at the mean value of the covariates in each regression. To provide a more
complete picture of the distribution of the estimated marginal, the fourth panel gives the percentage
of measurements where the share treated is estimated to have raised outcomes at diﬀerent levels
of conﬁdence (employing a one-sided test). The ﬁfth gives the percentage of measurements where
the share treated either raised or depressed outcomes (employing a two-sided test).
The estimated marginal eﬀect of share treated on outcomes at the mean value of covariates
is positive in treatment arms across all speciﬁcations. All measurements in the ﬁrst speciﬁcation
manifest a positive relationship at the 95% conﬁdence level. One-half to two-thirds of measurements
in other speciﬁcations manifest a positive relationship at the 95% level. In contrast, the estimated
marginal eﬀect of share treated on outcomes at the mean value of covariates is negative in control
arms. Indeed, between two-ﬁfths and all measurements manifest a negative relationship signiﬁcant
at the 95% conﬁdence level. Importantly, the F-tests of the eﬀects of share treated and various
covariates interacted with the share treated are statistically signiﬁcant in both treatment and
control arms across all speciﬁcation.
If the covariates of a speciﬁcation are able to control for selection, these ﬁndings suggest that the
treatment arms of H2-blocker trials manifest signiﬁcant evidence of placebo eﬀects, but the control
arms do not. If the covariates do not fully control for selection, then both arms of these trials
manifest signiﬁcant evidence of placebo eﬀects. The treatment arms do so because they manifest
a positive relationship between share treated and outcomes; the control arms do so because they
manifest a non-zero relationship. The results of the F-tests do not permit one to conclude that
placebo eﬀects fail to operate through any natural subset of variables.
Table 4 presents results for the remaining classes of anti-ulcer drugs, though F-tests are omit-
ted. Arms treated with prostaglandins manifest weak evidence of placebo eﬀects. While no arms
manifest evidence of a positive relationship, nearly all manifest a non-zero relationship at the 95%
17conﬁdence level under speciﬁcations one and two. However, the sample size of these regressions is
rather small. Arms treated with proton-pump inhibitors manifest moderate evidence of placebo
eﬀects. Around a quarter of measurements manifest a signiﬁcant positive relationship in speciﬁ-
cations two to four. At least a quarter, and often nearly all, measurements manifest evidence of a
non-zero relationship at the 90% conﬁdence level.
Turning to the control arms of these trials, one ﬁnds moderate evidence of placebo eﬀects
in the control arms of prostaglandin trials. Over one-half of measurements manifest a positive
relationship in speciﬁcations three and four. Around a third of measurements on control arms
of proton-pump inhibitor trials manifest evidence of a positive relationship under speciﬁcations
three and four. Around three-quarters of measurements manifest evidence of a signiﬁcant non-zero
relationship in speciﬁcations two through four. (There appears to be stronger evidence of placebo
eﬀects in speciﬁcations 3 and 4 for each drug and arm, perhaps because subject-level covariates do
a better job of picking up the selection eﬀects, permitting dj to focus on placebo eﬀects.)
Only trials where published reports conﬁrm that subjects were asked for informed consent were
included in these regressions. The sample also contains, however, 28 trials of H2-blockers where
it cannot be conﬁrmed that informed consent was requested. Regressions employing only these
trials reveal diminished evidence of placebo eﬀects in speciﬁcation one and two. The remaining
speciﬁcations cannot be estimated because of the small sample size. (Results omitted.) This
ﬁnding is consistent with the assumption that individuals learn the probability of receiving the
experimental treatment via informed consent. Without this disclosure, an individual’s beliefs
about the probability of treatment are unrelated to the actual share treated. Therefore, outcomes,
even if they depend on beliefs, should be invariant to the share treated in a trial.
5C O N C L U S I O N
This paper provides evidence of placebo eﬀects in blinded, parallel-arm RCTs of H2-blockers and
proton-pump inhibitors. This ﬁnding has important clinical implications. Placebo eﬀects under-
mine the internal validity of clinical trials by causing investigators to underestimate the eﬀect of
treatment on the treated. Outside the context of trials, enrollees would know whether they are
taking medication. Inside a blinded trial, they do not. Those randomized into the experimental-
18treatment group underperform – relative to those taking the same treatment outside the trial –
because they think there is a chance they are getting the less valuable control treatment. Con-
versely, those randomized into the control group overperform because there is chance they may be
getting the more valuable experimental treatment. The diﬀerence in mean outcomes across the
two groups will therefore be less than the diﬀerence in outcomes outside the trial.
T h es i z eo ft h i sb i a sm a yb es i g n i ﬁcant. Using table 2, the diﬀerence-in-means estimator sug-
gests that the physiological eﬀect of H2- b l o c k e r si sa2.4% increase in the daily healing rate. The
size of placebo eﬀects and thus the extent of bias due to their omission from estimates of treatment
eﬀects can be approximated by the estimated marginal eﬀect of share treated on outcomes. Spec-
iﬁcation two in table 3 suggests that the estimated marginal may be as large as a 1.2% increase
in the daily health rate. In other words, placebo eﬀects may be 50% as large as the physiological
eﬀect of H2-blockers and that standard estimates of the treatment eﬀect of these drugs is one-third
smaller than they should be.
Nevertheless, further investigation is required before placebo eﬀects can be labeled a serious and
general medical phenomenon. This research should proceed in two directions. One is theoretical.
This paper assumes health outcomes follow a simple linear model and examines only one type
of trial. It would be useful to have a more general test for placebo eﬀects that relaxes these
restrictions. A second direction for research is application to other medical drugs and ailments.
This is necessary to dispel concern that evidence of placebo eﬀects in this paper are an artifact of
data from ulcer trials.
If placebo eﬀect are found to be a widespread phenomenon, two questions will naturally follow.
First, why do beliefs aﬀect outcomes? One theory is that placebo eﬀect are a physiological
phenomenon. Perhaps knowledge of a higher probability of treatment triggered greater production
of mucous lining in subjects. An alternative theory is that placebo eﬀects are behavioral. Perhaps
knowledge of a higher probability of treatment caused subjects to take greater care of themselves
by, e.g., reducing their consumption of caﬀeine. Because investigators did not observe this, it
appears as if the share treated directly raised outcomes. Although both explanations imply that
investigators underestimate treatment eﬀects, this paper does not provide enough information to
discriminate between these theories.
Second, can placebo eﬀects be used for therapeutic purposes? For example, can a doctor cure
19a patient by suggesting, e.g., that a drug is more eﬀective than it really is? If so, and if fooling
patients is less costly than producing drugs, then placebo eﬀects may be able to reduce the costs of
health care. The existence of rational expectations may limit the productivity of placebo eﬀects
as a long-term cost-cutting measure. But the short-run cost savings might be non-trivial.
A PROOFS
Proposition 3. All expectations are taken with respect to gπ. Independence of ˜ πki and π0i
for k =1 ,2 implies that ∂E[π1i|˜ π1i > ˜ π2i/d]/∂d =0and ∂E[π1i|˜ π1i > ˜ π2i/d]/∂d = ∂E[˜ π1i|˜ π1i >
˜ π2i/d]/∂d.G i v e n ˜ πki > 0,f o rk =1 ,2, E[˜ π1i|˜ π1i > ˜ π2i/d]=E[˜ π1i|ln ˜ π1i − ln ˜ π2i > −lnd].
Because lnx is monotone increasing in x,
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Because Wi and Vi are independent, E [ln ˜ π1i|ln ˜ π1i − ln ˜ π2i > −lnd]=µ1+b1E(Wi|Wi >c (d,µ)),
where c(d,µ)=−(µ1 − µ2) − lnd.
Log-concavity or log-convexity of (ln ˜ π1i,ln ˜ π2i) implies log-concavity or log-convexity, respec-
tively, of Wi, by corollary 2 in An (An, 1998). Propositions 1 and 2 in Heckman and Hon-
ore (Heckman and Honore, 1990) demonstrate that log-concavity or log-convexity of Wi implies
∂E[Wi|Wi ≥ c]/∂c ≥ 0. Therefore,










Because ∂c(d,µ)/∂d < 0, ∂E[ln ˜ π1i|ln ˜ π1i − ln ˜ π2i > −lnd]/∂d ≤ 0 so long as σ11 >σ 12.T h i s
condition is the same as ρ12 <σ 1/σ2. Truncation of the range of ˜ πki at, e.g., one does not alter
this result (An, 1996).
Proposition 4. All expectations are taken with respect to gπ.B y ( 1 )
∂E[yki|˜ π1i > ˜ π2i/d]
∂d
=( 1− ak)
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20Working backwards, the selection equation (2) implies ˜ π1i > 0. By assumption, ∂E[π0i|˜ π1i >
˜ π2i/d]/∂d =0 . The proof to Proposition 3 demonstrates that sign(∂E[˜ π1i|˜ π1i > ˜ π2i/d]/∂d)=
sign(∂E[π1i|˜ π1i > ˜ π2i/d]/∂d),s o∂E[˜ π1i|˜ π1i > ˜ π2i/d]/∂d ≤ 0.B y ( 3 ) ,
∂E[pki|˜ π1i > ˜ π2i/d]
∂d
=
∂E[f (πki)|˜ π1i > ˜ π2i/d]
∂d
+
∂E[vki|˜ π1i > ˜ π2i/d]
∂d
.
The last term is zero because vki is assumed independent of πk0i0 for all (k0,i 0) and of vk0i0 for
all (k0,i 0) except (k0 = k,i0 = i).S i n c e f0 > 0,s i g n (∂E[f (πki)|˜ π1i > ˜ π2i/d]) =sign(∂E[πki|˜ π1i >
˜ π2i/d]).S o ∂E[p1i|˜ π1i > ˜ π2i/d]/∂d ≤ 0 and ∂E[p0i|˜ π1i > ˜ π2i/d]/∂d =0 .I f t h e r e a r e n o p l a c e b o
eﬀects, i.e., ak =0 ,t h e n∂E[y1i|˜ π1i > ˜ π2i/d]/∂d ≤ 0 and ∂E[y0i|˜ π1i > ˜ π2i/d]/∂d =0 .I f , h o w e v e r ,
there exist placebo eﬀects, the sign of ∂E[yki|˜ π1i > ˜ π2i/d]/∂d is ambiguous.
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22Table 1: Summary of tests for placebo eﬀects.
Prediction for
Conditions ∂E[yk|BT]/∂d
Self- Corr Consider Treatment Control
selection (πk,p k) plac. eﬀect Other group group
No . . . + +
Yes 0 . . +/— +/—
Yes + No
˜ πk, π0 indep.;˜ π log concave
or convex; Wi, Vi uncorrel.
+ +/—
Yes + Yes Same; d>0.5 + +/—
Table 2: Summary statistics on data from ulcer trials, by drug type and arm.
Treatment H2-Blockers Prostaglandins PPIs
Obs. Mean SD Obs. Mean SD Obs. Mean SD
Treatment arm
Share of subjects not given control 266 0.88 0.20 46 0.56 0.08 97 0.61 0.16
Share of arms in placebo-control trials 266 0.21 0.41 46 0.47 0.50 97 0.08 0.27
Share in antacid-control trials 266 0.05 0.22 46 0.00 0.00 97 0.00 0.00
Share in lower-class drug control trials 266 0.02 0.16 46 0.53 0.50 97 0.84 0.36
Share in same-class drug control trials 266 0.72 0.45 46 0.00 0.00 97 0.08 0.27
Number enrolled 266 186 144 46 123 110 97 110 40
Number evaluated (per protocol) 266 170 130 46 108 96 97 102 37
Share of subjs. not healed (method 1) 266 0.23 0.17 46 0.36 0.18 97 0.22 0.18
Daily hazard rate (meth. 1) 253 0.049 0.014 46 0.036 0.018 82 0.087 0.029
Antacids permitted in trial (1-5)? 266 3.6 0.7 46 3.5 0.6 97 3.1 1.2
Frequency of dosage (times/day) 266 1.8 1.0 46 2.8 1.0 97 1.2 0.7
Total daily dosage (mg) 266 0.440 0.358 46 0.093 0.233 97 0.028 0.018
Share male 252 0.72 0.07 41 0.73 0.09 95 0.70 0.09
Share that smoke 221 0.60 0.43 43 0.54 0.13 91 0.49 0.11
Average age (years) of subjs. 247 46 4 41 44 5 87 46 5
Control arm
Share of subjects not given control 94 0.56 0.11 40 0.53 0.07 67 0.53 0.08
Share of arms in placebo-control trials 94 0.77 0.43 40 0.39 0.49 67 0.04 0.19
Share in antacid-control trials 94 0.30 0.46 40 0.00 0.00 67 0.00 0.00
Share in lower-class drug control trials 94 0.00 0.00 40 0.61 0.49 67 0.96 0.19
Share in same-class drug control trials 94 0.00 0.00 40 0.00 0.00 67 0.00 0.00
Number enrolled 94 86 84 40 130 116 67 113 39
Number evaluated (per protocol) 94 76 75 40 117 105 67 104 38
Share of subjs. not healed (meth. 1) 94 0.57 0.23 39 0.36 0.28 67 0.36 0.22
Daily hazard rate (meth. 1) 93 0.025 0.017 38 0.040 0.021 66 0.055 0.021
Antacids permitted in trial (1-5)? 94 3.3 1.0 40 3.5 0.6 67 3.2 1.2
Share male 85 0.76 0.10 35 0.77 0.09 65 0.70 0.09
Share that smoke 67 0.64 0.12 37 0.52 0.11 61 0.49 0.14
Average age (years) of subjs. 76 45 5 35 44 5 59 46 6
23Table 3: Evidence of placebo eﬀects from H2-blocker trials.
Arm Treatment Control
Specification 1 2 3 4† 1 2 3 4†
Studies 93 93 63 63 93 93 63 63
Arms 157 157 121 121 63 63 42 42
Obs./Meas. 253 253 202 202 93 93 63 63
Subjects 12305 12305 9221 9221 2554 2554 1880 1880
F-tests of joint significance of coefficients on
d 61.4 10.5 3.9 0.6 78.3 5.9 7.8 8.3
P-value 0.0 0.0 0.1 0.4 0.0 0.0 0.0 0.0
Trial variables * d 86.8 163.8 0.5 2.1
0.0 0.0 0.5 0.2
Subject variables * d 55.4 66.8 19.9 29.0
0.0 0.0 0.0 0.0
d and all interactions 104.2 425.0 67.6 28.3 42.8 46.1
0.0 0.0 0.0 0.0
Estimated marginal at mean x
Estimate 0.011 0.011 0.016 0.006 -0.014 -0.022 -0.033 -0.029
Std. err. 0.001 0.003 0.002 0.002 0.002 0.007 0.011 0.010
Measurements manifesting positive relationship (percent, by conf. level)
At all 100 74 68 77 0 0 22 17
At 85% 100 70 60 70 0 0 16 16
At 95% 100 66 49 66 0 0 10 16
Measurements manifesting a non-zero relationship (percent, by conf. level)
At 85% 100 89 64 82 100 97 73 70
At 95% 100 87 61 78 100 38 57 62
24Table 4: Evidence of placebo eﬀects in prostaglandin and PPI trials.
Treatment Prostagladin PPI
Specification 1 2 3 4 1 2 3 4
Treatment arms
Studies 38 38 33 33 66 66 56 56
Obs./meas. 46 46 46 46 82 82 70 70
Subjects 1497 1497 1497 1497 3547 3547 2977 2977
Estimated marginal effect of share treated on the daily hazard (at mean x)
Estimate -0.038 -28.3 -0.038 -0.038 -0.022 0.005 -0.062 -0.030
Std. err. 0.012 3.927 0.012 0.012 0.013 0.015 0.026 0.013
Measurements manifesting positive relationship (percent, by conf. level)
A t  9 0 % 0000 0 2 0 3 0 3 6
A t  9 5 % 0000 0 2 0 3 0 3 6
Measurements manifesting a non-zero relationship (percent, by conf. level)
At 90% 100 87 100 100 100 29 64 84
At 95% 100 87 100 100 0 22 64 84
Control arms †
Obs./meas. 38 38 33 33 66 66 56 56
Subjects 1171 1171 1069 1069 2686 2686 2233 2233
Estimated marginal effect of share treated on the daily hazard (at mean x)
Estimate -0.020 -0.082 0.262 0.389 0.014 0.01 -0.02 -0.02
Std. err. 0.043 0.039 0.098 0.126 0 0.08 0.28 0.29
Measurements manifesting positive relationship (percent, by conf. level)
At 90% 0 0 61 64 0 15 36 39
At 95% 0 0 61 64 0 15 32 32
Measurements manifesting a non-zero relationship (percent, by conf. level)
At 90% 0 79 73 82 0 79 75 75
At 95% 0 79 58 82 0 79 70 75
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